TransMedics Group, Inc.
TMDX
$117.38
$2.201.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.68% | 48.21% | 49.83% | 63.72% | 117.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.68% | 48.21% | 49.83% | 63.72% | 117.87% |
| Cost of Revenue | 34.94% | 49.94% | 49.21% | 85.95% | 186.47% |
| Gross Profit | 39.46% | 47.14% | 50.27% | 49.64% | 88.51% |
| SG&A Expenses | 2.78% | 20.64% | 44.06% | 39.16% | 46.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.67% | 37.50% | 47.55% | 55.19% | 90.73% |
| Operating Income | 192.35% | 120.94% | 87.79% | 449.33% | 1,480.57% |
| Income Before Tax | 197.72% | 115.25% | 80.92% | 115.76% | 1,340.10% |
| Income Tax Expenses | 3,209.76% | 407.14% | 178.57% | 101.92% | -295.24% |
| Earnings from Continuing Operations | 186.26% | 110.56% | 70.11% | 116.58% | 1,318.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 186.26% | 110.56% | 70.11% | 116.58% | 1,318.18% |
| EBIT | 192.35% | 120.94% | 87.79% | 449.33% | 1,480.57% |
| EBITDA | 153.10% | 100.80% | 74.51% | 1,081.82% | 3,419.96% |
| EPS Basic | 179.55% | 104.57% | 65.26% | 116.18% | 1,295.45% |
| Normalized Basic EPS | 190.80% | 109.14% | 15.76% | 1,368.52% | 1,319.68% |
| EPS Diluted | 162.49% | 100.63% | 76.83% | 115.38% | 1,236.36% |
| Normalized Diluted EPS | 159.11% | 86.97% | 15.76% | 1,277.78% | 1,244.68% |
| Average Basic Shares Outstanding | 2.39% | 2.93% | 2.90% | 2.54% | 1.76% |
| Average Diluted Shares Outstanding | 14.94% | 15.10% | 3.02% | 9.41% | 8.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |